Recent Company News

• 06:51 AM ET Aug 25, 2026
  

  StreetAccount Metrics Recap - Shanghai Fosun Pharmaceutical (Group) Co. H1 Earnings (HK$17.31, 0.00)

• 06:49 AM ET Aug 25, 2026
  

  Shanghai Fosun Pharmaceutical (Group) Co. reports H1 CAS net income attributable CNY1.72B vs year-ago CNY1.70B (HK$17.31, 0.00)

• 11:25 PM ET Aug 19, 2026
  

  StreetAccount Summary - Trading higher/lower: China mid-morning

• 10:49 PM ET Aug 19, 2026
  

  StreetAccount Summary - Hong Kong unusual volume traders

• 07:59 PM ET Aug 16, 2026
  

  Shanghai Henlius Biotech enters licensing collaboration with Sandoz for up to 10 biosimilars; initial three worth up to $314M (HK$67.30, 0.00)

• 04:31 AM ET Aug 13, 2026
  

  Fosun Pharmaceutical (Group) unit initiates phase II mainland China study of FXS7553 for chronic obstructive pulmonary disease (HK$17.04, 0.00)

• 12:08 PM ET Aug 10, 2026
  

  StreetAccount M&A Summary: Week of 3-Aug

• 08:02 AM ET Aug 07, 2026
  

  Shanghai Fosun Pharmaceutical (Group) Co. obtains marketing approval in China for dobutamine hydrochloride injection in reduced myocardial contractility (HK$17.04, 0.00)

• 07:59 AM ET Aug 07, 2026
  

  Shanghai Fosun Pharmaceutical (Group) Co. obtains marketing approval in China for its levosalbutamol hydrochloride nebuliser solution (HK$17.04, 0.00)